Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports. The company’s device is designed for the continuous, subcutaneous delivery of exenatide in people with Type II diabetes. It was rejected by the U.S. […]
Featured
Delcath touts 500th commercial Chemosat treatment in Europe
Delcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system. The drug-device combo has been available in certain European markets since 2012. “This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for […]
Amgen swings to a loss in Q4 after $6B hit from tax reform
Shares in Amgen (NSDQ:AMGN) rose slightly today after the biotech missed expectations on Wall Street with its fourth-quarter earnings, but topped EPS estimates for the year ahead. The Thousand Oaks, Calif.-based company swung to a net loss in Q4 thanks to a $6 billion tax charge, posting -$4.26 billion on sales of $5.8 billion in the […]
The flu season is making a shortage of IV fluids worse – here’s what the FDA is doing about it
This year’s flu season has been exceptionally bad – it’s already claimed the lives of dozens of kids and it’s more widespread than any other year on record, according to the Centers for Disease Control and Prevention. It’s also making a shortage of intravenous fluids and IV bags worse than it already is. IV saline […]
Anika collabs to develop injectable stem cell therapy for osteoarthritis
Anika Therapeutics (NSDQ:ANIK) has inked an agreement with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy to treat osteoarthritis. As a result of the three-year research collaboration, the group hopes to have a lead candidate that it can take into clinical trials. “We are very excited […]
OncoSec Medical prices $20m public offering
OncoSec Medical (NSDQ:ONCS) today priced an underwritten public offering of 13,333,334 shares of its common stock at $1.50 apiece. The San Diego, Calif.-based company expects the offering to bring in $20 million to help fund its Phase II melanoma trial, as well as other clinical and R&D activities. As part of the offering, OncoSec gave underwriters […]
Court dismisses class action suit against InfuSystem
The U.S. District Court for the Central District of California has dismissed a class action lawsuit against InfuSystem (NYSE:INFU) alleging that the company, its ex-CEO and former chief finance executive violated federal securities laws by misleading investors with its financial statements. The case was brought against InfuSystem in Nov. 2016, after the company and its […]
Novocure touts quality-of-life analysis for glioblastoma patients treated with Optune-chemo combo
Novocure (NSDQ:NVCR) today touted an analysis published in JAMA Oncology showing that its Optune-temozolomide combination helped newly-diagnosed glioblastoma patients live longer without hurting their quality of life. In a Phase III pivotal trial, researchers found that a higher proportion of patients treated with Optune and temozolomide reported stable or improved quality of life measures compared to those […]
Shares in Novo Nordisk sink after Q4 earnings, sales disappoint
Shares in Novo Nordisk (NYSE:NVO) fell today after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results. The Denmark-based company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the […]
Baxter posts Street-beating Q4 earnings, sales
Shares in Baxter (NYSE:BAX) fell slightly this morning after the company topped expectations on Wall Street with its fourth quarter and full-year results. The Deerfield, Ill.-based company swung to a loss in Q4 thanks to a $322 million hit from the recently-enacted U.S. tax reform legislation. Baxter posted -$71 million in net losses for the quarter […]